NCT06503848View on ClinicalTrials.gov

Migraine Attack Treatment Response Molecular and Clinical BiOmarkers (MAMBO) Phase I

RecruitingOBSERVATIONAL
Enrollment

108

Participants

Timeline

Start Date

January 25, 2024

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Migraine Disorders
Interventions
DRUG

Sumatriptan

Register the response to treatment and headache characteristics.

Trial Locations (1)

Unknown

RECRUITING

Hospital Universitari Vall d'Hebron, Barcelona

All Listed Sponsors
collaborator

Instituto de Salud Carlos III

OTHER_GOV

lead

Hospital Universitari Vall d'Hebron Research Institute

OTHER